Stock is still over valued The company is not worth the current market cap even at this price. NASH is worth nothing. The oncology program is finished. They attempted a phase 1 trial with an already approved drug and could not even clear that very low hurdle. All profit from the commercialized drugs belongs to Marathon for a very long time. TH is left with nothing